Rhythm 2025 Q2 Earnings Wider Losses Amid Strong Revenue Growth

Rhythm Pharmaceuticals (RYTM) reported its fiscal 2025 Q2 earnings on August 5, 2025. The company delivered a 66.8% year-over-year revenue increase to $48.50 million, but its losses widened. Despite the revenue beat, the earnings report showed a 36.4% increase in per-share losses and a 44.5% rise in total net loss.

Rhythm’s total revenue soared to $48.50 million in Q2 2025, a significant jump of 66.8% compared to $29.08 million in the same period in 2024. The company’s product revenue, net, accounted for the entirety of its total revenue, reflecting the structure of its current offerings and market focus.

Rhythm’s financial performance deteriorated in terms of profitability, with net income turning sharply negative. The company reported a per-share loss of $0.75 in Q2 2025, a 36.4% increase in losses compared to the prior year’s $0.55. Its total net loss also widened to $46.63 million, representing a 44.5% increase from $32.26 million in Q2 2024.

Post-earnings, RYTM’s stock saw positive price momentum, rising 1.58% on the day, 3.43% for the week, and 34.67% month-to-date. A strategy of buying RYTM after earnings beat and selling after 30 days achieved a 429.31% return, with a Sharpe ratio of 0.53. However, the strategy’s maximum drawdown was 0.00%, suggesting it may not be robust across all market conditions.

The CEO emphasized progress in the melanocortin-4 receptor agonism platform, strong clinical data for key drugs, and an upsized public offering that bolstered the balance sheet. The company remains optimistic about expanding setmelanotide into new indications and advancing therapies for rare diseases.

Rhythm expects to file regulatory submissions for setmelanotide in acquired hypothalamic obesity in Q3 2025, share preliminary Prader-Willi syndrome results by year-end, and complete enrollment in a Phase 1, Part C trial of RM-718.

Additional News
On August 6, 2025, a news report titled “Rhythm Pharmaceuticals outlines 29% quarterly revenue…” was published, though the content is inaccessible. Based on the title, it appears Rhythm is highlighting strong sequential revenue growth. No further specific financial details or earnings metrics are available. This news, along with others not accessible, suggests ongoing business development, potentially tied to its recent public offering and clinical trial progress.